Cargando…

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

BACKGROUND: To examine the expression of type 1 plasminogen inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC), and its possible association with microvessel density (MVD), the expression of thrombospondin-1 (TSP-1), nuclear grade, tumour stage, continuously coded tumour size (CCTS) and to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zubac, Dragomir P, Wentzel-Larsen, Tore, Seidal, Tomas, Bostad, Leif
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002359/ https://www.ncbi.nlm.nih.gov/pubmed/21129210 http://dx.doi.org/10.1186/1471-2490-10-20

Ejemplares similares

The prognostic relevance of interactions between venous invasion, lymph node involvement and distant metastases in renal cell carcinoma after radical nephrectomy
por: Zubac, Dragomir P, et al.
Publicado: (2008)

PAI-1, the Plasminogen System, and Skeletal Muscle
por: Rahman, Fasih Ahmad, et al.
Publicado: (2020)

Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

A multiomics disease progression signature of low-risk ccRCC
por: Strauss, Philipp, et al.
Publicado: (2022)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
por: White, Marquitta J., et al.
Publicado: (2015)

Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
por: Party, Hélène, et al.
Publicado: (2019)

Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix
Publicado: (1991)

Characterization of the Prognostic Values of the CXCR1-7 in Clear Cell Renal Cell Carcinoma (ccRCC) Microenvironment
por: Wu, Zhulin, et al.
Publicado: (2020)

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997)

Changes in plasminogen activator inhibitor-1 (PAI-1) in patients with severe sepsis or septic shock
por: Ikeda, T, et al.
Publicado: (2002)

Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma
por: Kluft, C.
Publicado: (2000)

Gastric Expression of Plasminogen Activator Inhibitor (PAI)-1 Is Associated with Hyperphagia and Obesity in Mice
por: Kenny, Susan, et al.
Publicado: (2013)

Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells
por: Roy, Ananya, et al.
Publicado: (2015)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells
Publicado: (1987)

Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC)
por: Ricketts, Christopher J., et al.
Publicado: (2015)

Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
por: Lorente, L, et al.
Publicado: (2009)

Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Ghatalia, Pooja, et al.
Publicado: (2018)

Increased expression of urokinase type plasminogen activator(u-PA), plasminogen activator inhibitor-1(PAI-1), and collagenases in Caco-2 cells infected by Salmonella typhimurium.
por: Park, C. G., et al.
Publicado: (1997)

The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies
por: Bajou, Khalid, et al.
Publicado: (2001)

Plasminogen activator inhibitor (PAI)-1 suppresses inhibition of gastric emptying by cholecystokinin (CCK) in mice()
por: Gamble, Joanne, et al.
Publicado: (2013)

Tat-hspb1 Suppresses Clear Cell Renal Cell Carcinoma (ccRCC) Growth via Lysosomal Membrane Permeabilization
por: Zhang, Lin, et al.
Publicado: (2022)

Fibronectin, Plasminogen Activator Inhibitor Type 1 (PAI-1) And Uterine Artery Doppler Velocimetry as Markers of Preeclampsia
por: Bodova, Kristina Biskupska, et al.
Publicado: (2011)

Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women
por: Ozgen, Merih, et al.
Publicado: (2012)

PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent
por: Hohensinner, Philipp J., et al.
Publicado: (2017)

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in  Clear - Cell Renal Cell Carcinoma (ccRCC)
por: Bielecka, Zofia F., et al.
Publicado: (2013)

Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC)
por: Zhengqi, Qiu, et al.
Publicado: (2021)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

AB090. Establishment of prediction model of progression after radical nephrectomy or partial nephrectomy for Chinese patients with clear cell renal cell carcinoma
por: Zhao, Yao-Rui, et al.
Publicado: (2015)

Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women
por: Cho, Hee Young, et al.
Publicado: (2021)

Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders
por: Mennesson, Marie, et al.
Publicado: (2023)

PSUN171 CORRELATIONS BETWEEN SERUM AND TEAR PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) AND TISSUE PLASMINOGEN ACTIVATOR (tPA) IN PATIENTS WITH DIABETIC RETINOPATHY
por: Jasmiad, Nurbadriah, et al.
Publicado: (2022)

Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines
por: Schilling, Daniela, et al.
Publicado: (2007)

Laparoscopic radical nephrectomy versus open radical nephrectomy in T1-T3 renal tumors: An outcome analysis
por: Ganpule, Arvind P., et al.
Publicado: (2008)

Predictive role of plasminogen-activator-inhibitor-1 (PAI-1) in non-ST-segment elevation acute coronary syndrome
por: Sinkovic, A, et al.
Publicado: (2002)

Serum plasminogen activator inhibitor 1 (PAI-1) and intra-ocular pressure (IOP): the Guangzhou biobank cohort study
por: Heggie, J, et al.
Publicado: (2012)

Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer
por: Gondek, Tomasz, et al.
Publicado: (2014)

Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility
por: Oh, Jisu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qhisdcgiainsrv8ovacdtea45h